Adicet Bio (ACET) CEO Chen Schor receives 55,000 stock options at $8.10

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Adicet Bio President & CEO Chen Schor received a new stock option award covering 55,000 shares of Common Stock. The options have an exercise price of $8.10 per share and expire on June 18, 2036.

The grant vests over four years, with 1/48th of the options vesting on each of the next 48 monthly anniversaries of the grant date. A portion of the vesting can accelerate if specific performance milestones are met, as long as Schor maintains a service relationship with Adicet Bio on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schor Chen

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	55,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 55,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 55,000 shares Exercise price: $8.10 per share Expiration date: June 18, 2036 +2 more

5 metrics

Option grant size 55,000 shares Stock Option (Right to Buy) granted to President & CEO

Exercise price $8.10 per share Conversion or exercise price for granted stock options

Expiration date June 18, 2036 Option expiration for CEO stock option grant

Underlying shares 55,000 shares Underlying common stock for the granted options

Vesting schedule 1/48th monthly over 48 months Time-based vesting with partial performance milestone acceleration

Key Terms

Stock Option (Right to Buy), exercise price, vesting, performance milestones

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price set at 8.1000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48th of the shares shall vest on each of the next forty-eight monthly anniversaries"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

performance milestones financial

"partial acceleration tied to certain performance milestones"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 06:51 PM Accepted by SEC EDGAR 06/23/2026 - 06:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schor Chen

(Last)

(First)

(Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON

MASSACHUSETTS

02116

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.1	06/19/2026		A		55,000		⁽¹⁾	06/18/2036	Common Stock	55,000	$0	55,000	D

Explanation of Responses:

1. 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

	/s/ Nick Harvey, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Adicet Bio (ACET) CEO Chen Schor report in this Form 4?

Chen Schor reported receiving a grant of stock options for 55,000 shares of Adicet Bio common stock. The options are a compensation award, not an open-market purchase or sale, and give the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Chen Schor’s new Adicet Bio (ACET) stock options?

The granted stock options have an exercise price of $8.10 per share. This means Schor can choose to buy Adicet Bio common shares at $8.10 in the future, regardless of the market price, once the options have vested and before they expire.

How many Adicet Bio (ACET) shares are covered by Chen Schor’s option grant?

The option award covers 55,000 underlying shares of Adicet Bio common stock. These shares are not issued immediately; they can be acquired over time if Schor exercises vested options at the stated $8.10 per share exercise price before expiration.

When do Chen Schor’s Adicet Bio (ACET) stock options vest?

The options vest in 48 equal monthly installments, with 1/48th of the grant vesting on each monthly anniversary of the grant date. Vesting is conditioned on Schor maintaining a service relationship with Adicet Bio on each vesting date, as described in the footnote.

Is there performance-based acceleration in Chen Schor’s Adicet Bio (ACET) option grant?

Yes. The footnote states there is partial acceleration tied to certain performance milestones. If those milestones are achieved and Schor continues his service relationship, some portion of the remaining unvested options may vest earlier than the regular monthly schedule.

When do Chen Schor’s new Adicet Bio (ACET) stock options expire?

The options expire on June 18, 2036, if not exercised earlier. After this expiration date, any unexercised options become worthless, so Schor must exercise vested options before that date to acquire the underlying common shares.